Section A: General questions about genital herpes
|
62
|
18
|
15
|
5
|
Q1: Genital herpes is the commonest cause of genital ulceration in developed countries (T-F-NS)* | 86 | 4 | 10 | – |
Q2: Proportion of HSV–1 causing genital herpes is decreasing (T–F–NS) | 53 | 4 | 41 | 2 |
Q3: GU medicine clinic attendees have higher prevalence of genital herpes than general population (T–F–NS) | 82 | 9 | 9 | 0.5 |
Q4: Incidence of neonatal herpes in UK per 100 000 live births (<2–20–200) | 27 | 56 | – | 17 |
Section B: Shedding, transmission, and clinical presentation
|
63
|
17
|
19
|
1
|
Q5: Majority of infected individuals with genital herpes are unaware of their infection (T–F–NS) | 57 | 28 | 15 | – |
Q6: Source partners in most transmission events are unaware of their infection (T–F–NS) | 73 | 11 | 15 | 0.5 |
Q7: Patients shed the virus and transmit it even in absence of clinical signs (T–F–NS) | 77 | 8 | 13 | 2 |
Q8: Most transmission occurs during periods of asymptomatic viral shedding (T–F–NS) | 44 | 19 | 36 | 1 |
Section C: Type specific serotesting of genital herpes
|
41
|
8
|
49
|
2
|
Q9: Positive serological test for HSV-2 essentially Indicates previous genital herpes infection (T–F–NS) | 48 | 9 | 41 | 2 |
Q10: Serological testing can differentiate between HSV-1 and HSV-2 (T–F–NS) | 43 | 3 | 51 | 3 |
Q11: Serological testing can differentiate between oral and genital HSV-1 infection (T–F–NS) | 31 | 12 | 54 | 2 |
Sections A + B:
|
63
| 17 | 17 | 3 |
Sections A + B + C: |
56
|
15
|
26
|
3
|
Section D: Attitude towards genital herpes serotesting:
| | | | |
Q12: Do you support the availability of this testing (at the present time) at least in GUM clinics? |
Yes
| No. | Not sure | No answer |
| 78% | 1.6% | 17.5% | 2.7% |
Q13: Do you see this testing used in routine screening for STDs or in selected cases? |
Routine
| Selected cases | | No answer |
| 76% | 21% | | 3% |